Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era

NCT02633202 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

338

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

RADIATION: IMRT
DRUG: Cisplatin

Sponsor

Sun Yat-sen University

Collaborators

Fifth Affiliated Hospital, Sun Yat-Sen University
Guilin Medical University, China
First People's Hospital of Foshan